On December 3, 2018, the board of directors (the Board") of Odonate Therapeutics, Inc. (the Company") appointed Laura Johnson Douglass to the Board and the Audit Committee of the Board to serve until the Company's 2019 Annual Meeting of Stockholders and until her successor is duly elected and qualified. Ms. Douglass is the President and Chief Executive Officer of Next Generation Clinical Research Consulting, Inc., a contract research organization servicing the pharmaceutical industry that she founded in 1999. Additionally, Ms. Douglass is the President and Chief Executive Officer of Eufaeria Biosciences, Inc.